# Tibolone and Raloxifene in Menopause

> Tibolone and raloxifene in menopause, with mechanism, bone and breast effects and stroke or thromboembolic risks, for NEET-PG Obstetrics and Gynaecology.

- Canonical URL: https://prepelephant.com/topics/neet-pg/obstetrics-and-gynaecology/tibolone-and-raloxifene-in-menopause
- Exam / course: NEET-PG · Subject: Obstetrics and Gynaecology
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-08
- Last updated: 2026-10-08
- Reference basis: Williams Gynecology; Novak's Gynecology; Dutta's Textbook of Gynecology
- How to cite: "Tibolone and Raloxifene in Menopause", PrepElephant, https://prepelephant.com/topics/neet-pg/obstetrics-and-gynaecology/tibolone-and-raloxifene-in-menopause

## Direct answer

Tibolone and raloxifene are tissue-selective agents that act as oestrogen in some organs and block it in others. Tibolone is a synthetic steroid that protects bone and relieves hot flushes, but it raises stroke risk and is contraindicated in breast cancer. Raloxifene is a selective oestrogen receptor modulator that protects bone and lowers invasive breast cancer risk, but it increases venous thromboembolism and can worsen hot flushes.

## What you must remember

- **Tibolone mechanism:** A synthetic steroid whose metabolites give oestrogenic, progestogenic and androgenic effects depending on the tissue.
- **Tibolone benefits:** It relieves vasomotor symptoms, reduces bone loss and protects the endometrium without a separate progestogen.
- **Tibolone risks:** It increases stroke risk and is contraindicated in breast cancer, unexplained bleeding and a history of stroke or venous thromboembolism.
- **Raloxifene mechanism:** A selective oestrogen receptor modulator that acts as an agonist in bone and an antagonist in breast tissue.
- **Raloxifene benefits:** It reduces vertebral fracture risk and invasive breast cancer risk, without endometrial stimulation.
- **Raloxifene risks:** It increases venous thromboembolism risk and can worsen hot flushes.
- **Standard dose:** Raloxifene is taken as 60 mg once daily in postmenopausal osteoporosis.

## A side-by-side comparison of the two agents

The two agents share a tissue-selective design but target different problems. Bone protection is common to both, but their vasomotor and thrombotic profiles differ sharply, so the table shows why they are not interchangeable.

| Feature | Tibolone | Raloxifene |
|---|---|---|
| Class | Synthetic steroid | Selective oestrogen receptor modulator |
| Bone | Reduces fracture risk | Reduces vertebral fracture risk |
| Hot flushes | Relieves them | Can worsen them |
| Breast | Contraindicated in breast cancer | Lowers invasive breast cancer risk |
| Endometrium | Progestogenic protection | No endometrial stimulation |
| Major risk | Stroke | Venous thromboembolism |

Tibolone suits symptomatic women with bone loss who have no stroke or breast risk. Raloxifene suits women whose main concern is vertebral fracture or breast cancer risk and who do not need symptom relief.

Before either agent is started, stroke, thromboembolic and breast cancer risks should be documented, and bone density assessed by DEXA. Calcium and vitamin D intake should be checked alongside either drug, because bone protection depends on adequate supply.

## High-yield comparisons

Each trap pairs a comparison with the contraindication examiners most often test.

- **Trap:** Using raloxifene to relieve hot flushes. — **Correct:** It often worsens vasomotor symptoms, so it suits bone or breast protection rather than symptom control.
- **Trap:** Expecting raloxifene to prevent hip fracture as bisphosphonates do. — **Correct:** Trials showed vertebral fracture reduction, and a hip fracture benefit was not established.
- **Trap:** Giving tibolone to a woman with a previous stroke. — **Correct:** A history of stroke is a contraindication, because tibolone increases stroke risk.
- **Trap:** Choosing raloxifene after a deep vein thrombosis. — **Correct:** Prior venous thromboembolism is a contraindication, because raloxifene increases thrombotic risk.

## Frequently asked questions

### Which tissue-selective agent is contraindicated after a stroke?

Tibolone is contraindicated after a stroke, because it increases stroke risk, particularly in older women. Raloxifene is avoided after venous thromboembolism, which is its own key contraindication. Hormone-free options should be considered after stroke, under specialist guidance.

### What is the standard daily dose of raloxifene in postmenopausal osteoporosis?

Raloxifene is taken as 60 mg once daily in postmenopausal osteoporosis. Adequate calcium and vitamin D intake is advised alongside it. Its effect on vertebral fracture is established, but it has not shown the hip fracture reduction seen with bisphosphonates.

### Why does raloxifene worsen hot flushes instead of relieving them?

Raloxifene acts as an oestrogen antagonist in some central tissues, and this is thought to explain the increase in hot flushes. The drug protects bone and breast tissue while doing so. Women who need symptom relief are usually better served by a different agent.

### Does tibolone need a separate progestogen for endometrial protection?

No, tibolone has progestogenic activity that protects the endometrium, so a separate progestogen is not usually added. This is one practical advantage over oestrogen-only therapy. Endometrial bleeding or thickening still needs evaluation, because the protection is not absolute.